HC Wainwright Reaffirms “Neutral” Rating for Atara Biotherapeutics (NASDAQ:ATRA)

Atara Biotherapeutics (NASDAQ:ATRA)‘s stock had its “neutral” rating reissued by HC Wainwright in a report issued on Wednesday,Benzinga reports.

ATRA has been the topic of a number of other reports. Rodman & Renshaw initiated coverage on Atara Biotherapeutics in a research report on Friday, December 20th. They issued a “buy” rating and a $25.00 price objective on the stock. Canaccord Genuity Group reduced their target price on shares of Atara Biotherapeutics from $21.00 to $17.00 and set a “buy” rating on the stock in a research note on Friday, January 17th. RODMAN&RENSHAW upgraded shares of Atara Biotherapeutics to a “strong-buy” rating in a research report on Friday, December 20th. Finally, TD Cowen raised shares of Atara Biotherapeutics to a “strong-buy” rating in a research note on Friday, November 29th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, three have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, Atara Biotherapeutics presently has an average rating of “Moderate Buy” and an average price target of $17.75.

Atara Biotherapeutics Stock Down 7.9 %

Atara Biotherapeutics stock opened at $6.05 on Wednesday. The stock has a 50-day simple moving average of $12.31 and a 200 day simple moving average of $10.00. The stock has a market capitalization of $34.85 million, a price-to-earnings ratio of -0.23 and a beta of 0.51. Atara Biotherapeutics has a 12-month low of $5.40 and a 12-month high of $39.50.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its earnings results on Tuesday, November 12th. The biotechnology company reported ($2.93) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.77) by $0.84. The company had revenue of $40.19 million during the quarter, compared to the consensus estimate of $23.00 million. During the same period in the prior year, the firm posted ($16.50) earnings per share. As a group, sell-side analysts anticipate that Atara Biotherapeutics will post -9.86 EPS for the current year.

Institutional Investors Weigh In On Atara Biotherapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of ATRA. Vestal Point Capital LP lifted its position in Atara Biotherapeutics by 11.3% during the 3rd quarter. Vestal Point Capital LP now owns 124,677 shares of the biotechnology company’s stock worth $1,014,000 after buying an additional 12,677 shares in the last quarter. Geode Capital Management LLC raised its holdings in Atara Biotherapeutics by 9.5% during the third quarter. Geode Capital Management LLC now owns 46,720 shares of the biotechnology company’s stock worth $380,000 after acquiring an additional 4,043 shares in the last quarter. FMR LLC boosted its position in Atara Biotherapeutics by 41.7% during the third quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock valued at $204,000 after purchasing an additional 7,381 shares during the last quarter. State Street Corp grew its stake in Atara Biotherapeutics by 52.3% in the third quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock valued at $182,000 after purchasing an additional 7,680 shares in the last quarter. Finally, Cubist Systematic Strategies LLC bought a new position in Atara Biotherapeutics in the second quarter valued at approximately $79,000. Institutional investors and hedge funds own 70.90% of the company’s stock.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.